吉贝尔(688566) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was CNY 209,545,575.24, representing a year-on-year increase of 5.74%[2] - Net profit attributable to shareholders decreased by 10.62% year-on-year to CNY 52,557,701.84[2] - The basic earnings per share for Q3 2024 was CNY 0.27, down 12.90% from the same period last year[2] - Total operating revenue for the first three quarters of 2024 reached CNY 643,207,277.90, an increase of 4.0% compared to CNY 616,974,946.31 in the same period of 2023[15] - Operating profit for the first three quarters of 2024 was CNY 200,916,397.16, up 13.4% from CNY 177,119,692.84 in the previous year[16] - Net profit attributable to shareholders of the parent company for the first three quarters of 2024 was CNY 174,563,672.90, representing a growth of 12.5% compared to CNY 155,068,445.62 in 2023[16] - Basic and diluted earnings per share for the first three quarters of 2024 were both CNY 0.91, an increase from CNY 0.83 in the same period last year[18] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 2,491,846,662.37, reflecting a 12.77% increase from the end of the previous year[3] - The total assets of the company reached CNY 2,491,846,662.37, up from CNY 2,209,668,213.23, representing a growth of 12.7%[14] - The company's current assets totaled approximately RMB 1.32 billion, up from RMB 1.13 billion in the previous year, indicating a year-over-year increase of around 17%[12] - The total liabilities decreased to approximately RMB 1.32 billion from RMB 1.38 billion, indicating a reduction of about 4.3%[12] - Total liabilities decreased to CNY 230,792,139.31 from CNY 299,249,332.90, reflecting a reduction of approximately 22.9%[14] - The total equity attributable to shareholders increased by 18.42% year-on-year to CNY 2,255,725,339.58[3] - Total equity attributable to shareholders of the parent company increased to CNY 2,255,725,339.58, up from CNY 1,904,838,829.13, marking a growth of 18.4%[14] Cash Flow - Cash flow from operating activities for the year-to-date increased by 77.88%, primarily due to higher cash receipts from sales[6] - In the first three quarters of 2024, Jiangsu Jibeier Pharmaceutical Co., Ltd. reported cash inflows from operating activities of CNY 746,171,527.20, an increase of 29.8% compared to CNY 575,128,479.21 in the same period of 2023[19] - The net cash flow from operating activities for the first three quarters of 2024 was CNY 169,962,425.71, up from CNY 95,548,318.75 in 2023, representing a growth of 77.6%[20] - Cash inflows from financing activities amounted to CNY 239,989,159.87 in the first three quarters of 2024, significantly higher than CNY 34,461,100.37 in the same period of 2023[21] - The net cash flow from financing activities improved to CNY 187,685,134.97 in 2024, compared to a negative CNY 10,804,883.63 in 2023[21] - The total cash and cash equivalents at the end of Q3 2024 stood at CNY 629,390,033.36, an increase from CNY 517,845,879.38 at the end of Q3 2023[21] Expenses - Research and development expenses totaled CNY 16,547,121.94, accounting for 7.90% of revenue, an increase of 1.09 percentage points compared to the same period last year[3] - Research and development expenses for the first three quarters of 2024 were CNY 31,163,217.53, down 26.0% from CNY 42,098,394.87 in the previous year[15] - Sales expenses increased to CNY 291,673,646.34, compared to CNY 280,725,066.96 in the same period of 2023, reflecting a rise of 3.4%[15] - The company reported a decrease in tax and surcharges to CNY 9,296,436.07 from CNY 7,269,068.80, indicating an increase of 28.0%[15] - The cash paid to employees and for employee benefits increased to CNY 174,344,919.66 in 2024, compared to CNY 161,058,884.67 in 2023, reflecting a rise of 8.0%[20] - The company’s cash outflows for taxes paid rose to CNY 95,089,353.44 in 2024, up from CNY 70,231,923.29 in 2023, marking an increase of 35.4%[20] Shareholder Information - The top ten shareholders held a combined 70.80% of the company's shares, with the largest shareholder owning 27.28%[8] - The company has not reported any significant changes in shareholder financing or stock lending activities during the reporting period[10] Strategic Developments - There are no new strategies or major product developments mentioned in the report for the upcoming quarters[10] - Jiangsu Jibeier Pharmaceutical Co., Ltd. has not adopted new accounting standards for the year 2024, as indicated in their report[22] Other Financial Metrics - The weighted average return on equity decreased by 0.89 percentage points to 2.39%[2] - The company reported non-recurring gains of CNY 1,689,064.39 for the current period[5] - Cash and cash equivalents decreased to approximately RMB 630 million from RMB 694 million, reflecting a decline of about 9%[11] - Trade receivables increased to approximately RMB 259.69 million, compared to RMB 228.85 million, marking an increase of about 13%[11] - Inventory rose to approximately RMB 34.72 million from RMB 29.51 million, which is an increase of about 17%[12] - The company's long-term equity investments slightly decreased to approximately RMB 122.85 million from RMB 126.19 million, a decline of about 2.6%[12] - The company reported a significant increase in trading financial assets, which rose to RMB 331 million from RMB 35 million, representing a growth of approximately 846%[11]